CL2019001014A1 - Métodos de tratamiento de afecciones relacionadas con la inflamación utilizando moduladores metabólicos y anti inflamatorios pluripotentes. - Google Patents

Métodos de tratamiento de afecciones relacionadas con la inflamación utilizando moduladores metabólicos y anti inflamatorios pluripotentes.

Info

Publication number
CL2019001014A1
CL2019001014A1 CL2019001014A CL2019001014A CL2019001014A1 CL 2019001014 A1 CL2019001014 A1 CL 2019001014A1 CL 2019001014 A CL2019001014 A CL 2019001014A CL 2019001014 A CL2019001014 A CL 2019001014A CL 2019001014 A1 CL2019001014 A1 CL 2019001014A1
Authority
CL
Chile
Prior art keywords
methods
inflammatory
related conditions
treating inflammation
metabolic modulators
Prior art date
Application number
CL2019001014A
Other languages
English (en)
Spanish (es)
Inventor
Batthyány Carlos
López Gloria
Escande Carlos
Rodriguez Duarte Jorge
Porcal Quinta Williams
Dapueto Capuccio Rosina
Galliussi Lopez German
Garat Nuñez María
Hill Marcelo
Segovia Mercedes
Original Assignee
Inst Pasteur De Montevideo
Univ La Republica
Carlos Batthyany
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Pasteur De Montevideo, Univ La Republica, Carlos Batthyany filed Critical Inst Pasteur De Montevideo
Publication of CL2019001014A1 publication Critical patent/CL2019001014A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2019001014A 2016-10-14 2019-04-13 Métodos de tratamiento de afecciones relacionadas con la inflamación utilizando moduladores metabólicos y anti inflamatorios pluripotentes. CL2019001014A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662408459P 2016-10-14 2016-10-14
US201762570973P 2017-10-11 2017-10-11

Publications (1)

Publication Number Publication Date
CL2019001014A1 true CL2019001014A1 (es) 2019-11-29

Family

ID=60382484

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019001014A CL2019001014A1 (es) 2016-10-14 2019-04-13 Métodos de tratamiento de afecciones relacionadas con la inflamación utilizando moduladores metabólicos y anti inflamatorios pluripotentes.

Country Status (9)

Country Link
US (3) US10537537B2 (https=)
EP (2) EP3525780B1 (https=)
JP (1) JP6923659B2 (https=)
CN (1) CN110325182B (https=)
AU (1) AU2017342167B2 (https=)
CL (1) CL2019001014A1 (https=)
ES (2) ES2886122T3 (https=)
MX (1) MX394475B (https=)
WO (1) WO2018069907A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190080A1 (ar) 2016-10-14 2019-04-11 Bayer Pharma AG مركبات مشتقة من 6-(1h-بيرازول-1-يل) بيريميدين-4- أمين مستبدل واستخداماتها
ES2886122T3 (es) 2016-10-14 2021-12-16 Inst Pasteur De Montevideo Moduladores antinflamatorios y metabólicos pluripotentes para el tratamiento de afecciones relacionadas con la inflamación
US11400066B2 (en) 2016-10-14 2022-08-02 Institut Pasteur De Montevideo Methods of treatment of inflammation related conditions using pluripotent anti-inflammatory and metabolic modulators
BR112020013152B1 (pt) * 2017-12-27 2023-05-09 Institut Pasteur De Montevideo Composto e composição farmacêutica
US10632132B2 (en) * 2018-01-24 2020-04-28 Carlos Batthyány Methods for treating heart transplant rejection
EP3852739A1 (en) * 2018-09-20 2021-07-28 Institut Pasteur De Montevideo Methods of treatment of inflammation related conditions using pluripotent anti-inflammatory and metabolic modulators
WO2025238423A2 (en) * 2024-05-14 2025-11-20 Institut Pasteur De Montevideo Methods of treating metabolic disorders and combination products for use in the same

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5113140B2 (https=) * 1972-01-13 1976-04-26
JPS5113140A (en) 1974-07-23 1976-02-02 Sankyo Alu Ind Kinzokuseitoshojino nakazan
ES2136581B1 (es) * 1998-05-27 2000-09-16 Uriach & Cia Sa J Uso de derivados del acido-2-hidroxi-4-trifluorometilbenzoico para la preparacion de medicamentos utiles para inhibir el factor de transcripcion nuclear nf-kb.
US20050187176A1 (en) * 2003-10-10 2005-08-25 Bates Paula J. Method for inhibiting NF-kappa B signaling and use to treat or prevent human diseases
US20060247263A1 (en) * 2005-04-19 2006-11-02 Amgen Inc. Substituted heterocyclic compounds and methods of use
US8933255B2 (en) * 2008-12-31 2015-01-13 Nitromega Corp. Nutraceuticals containing nitro fatty acids
WO2013167996A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
WO2015073527A1 (en) 2013-11-12 2015-05-21 Complexa, Inc. Nitroalkene tocopherols and analogs thereof for use in the treatment and prevention of inflammation related conditions
ES2886122T3 (es) 2016-10-14 2021-12-16 Inst Pasteur De Montevideo Moduladores antinflamatorios y metabólicos pluripotentes para el tratamiento de afecciones relacionadas con la inflamación
US11400066B2 (en) 2016-10-14 2022-08-02 Institut Pasteur De Montevideo Methods of treatment of inflammation related conditions using pluripotent anti-inflammatory and metabolic modulators
US10632132B2 (en) * 2018-01-24 2020-04-28 Carlos Batthyány Methods for treating heart transplant rejection
EP3852739A1 (en) 2018-09-20 2021-07-28 Institut Pasteur De Montevideo Methods of treatment of inflammation related conditions using pluripotent anti-inflammatory and metabolic modulators

Also Published As

Publication number Publication date
US12280029B2 (en) 2025-04-22
US20180104202A1 (en) 2018-04-19
US20220296546A1 (en) 2022-09-22
JP2019531356A (ja) 2019-10-31
JP6923659B2 (ja) 2021-08-25
ES2886122T3 (es) 2021-12-16
CN110325182B (zh) 2023-05-23
MX2019004402A (es) 2019-09-26
AU2017342167B2 (en) 2023-01-12
EP3878456A1 (en) 2021-09-15
US10537537B2 (en) 2020-01-21
MX394475B (es) 2025-03-24
EP3525780B1 (en) 2021-06-02
US20250352501A1 (en) 2025-11-20
CN110325182A (zh) 2019-10-11
EP3525780A1 (en) 2019-08-21
ES2945822T3 (es) 2023-07-07
WO2018069907A1 (en) 2018-04-19
EP3878456B1 (en) 2023-03-15
AU2017342167A1 (en) 2019-06-06

Similar Documents

Publication Publication Date Title
CL2019001014A1 (es) Métodos de tratamiento de afecciones relacionadas con la inflamación utilizando moduladores metabólicos y anti inflamatorios pluripotentes.
BR112017011536A2 (pt) terapias de combinação
MX2024000348A (es) Mavacamten para su uso en el tratamiento de la cardiomiopatia hipertrofica.
BR112018067434A2 (pt) partículas de microagulha, composições e métodos de tratamento e entrega de uma substância de interesse
UY35313A (es) Antiadhesion de leucocitos para mitigar los potenciales eventos adversos causados por los dominios de unión específicos de cd3
CO2017001493A2 (es) Kits que comprenden inhibidores tigit y agentes anticáncer
DOP2017000097A (es) Composiciones y métodos de uso para tratar trastornos metabólicos
PH12019501323A1 (en) Compositions comprising sulfated polysaccharides
MX2024012816A (es) Metodos para tratar y/o prevenir la enfermedad de injerto contra huesped y/o la hemorragia alveolar difusa y/o la enfermedad venooclusiva asociada al trasplante de celulas madre hematopoyeticas
EP3402543A4 (en) CARDIOSPHERE-GENERATING CELLS AND EXOSOMES SECRETED BY SUCH CELLS IN THE TREATMENT OF HEART FAILURES WITH PRESERVED SELECTION
MX2023000796A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
MX2017005030A (es) Composiciones y metodos para el tratamiento de la disfusion de la glandula de meibomio.
MX2015013948A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
PE20180260A1 (es) Metodos y kits para tratar la depresion
ECSP20000655A (es) AGENTES DE iARN PARA LA INHIBICIÓN DE LA EXPRESIÓN DE ALFA-ENaC Y MÉTODOS DE USO
PE20191407A1 (es) Uso de gaboxadol en el tratamiento de tinnitus
EA201691808A8 (ru) Кортикостероидные композиции для местного применения
SI3723739T1 (sl) Paraziticidni pripravki na osnovi izoksazolina in njihova uporaba za zdravljenje blefaritisa
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
EA201991175A1 (ru) Применение в медицине интерферона-лямбда для лечения фиброза
DOP2018000034A (es) Combinaciones de un anticuerpo ox40 y un modulador de tlr4 y usos de las mismas
MX2018013873A (es) Irinotecan nanoliposomico para usarse en el tratamiento del cancer de pulmon de celulas pequeñas.
MX2017015532A (es) Terapia de combinacion pac-1.
CO2019002245A2 (es) Combinación de agonistas de fxr
MX2021011598A (es) Uso de mir101 o mir128 en el tratamiento de trastornos convulsivos.